Literature DB >> 35099759

Nanozyme-Based Enhanced Cancer Immunotherapy.

Ngoc Man Phan1, Thanh Loc Nguyen1, Jaeyun Kim2,3,4,5.   

Abstract

Catalytic nanoparticles with natural enzyme-mimicking properties, known as nanozymes, have emerged as excellent candidate materials for cancer immunotherapy. Owing to their enzymatic activities, artificial nanozymes not only serve as responsive carriers to load drugs and therapeutic molecules for cancer treatment, but also act as enzymes for modulating the immunosuppression of the tumor microenvironment (TME) via the catalytic activities of catalase, peroxidase, superoxide dismutase, and oxidase. The immunosuppressive pro-tumor TME can be reversed to the immunoactive anti-tumor TME by utilizing both reactive oxygen species (ROS)-generating and ROS-scavenging nanozymes, which enhance the efficacy of cancer immunotherapy. In this review, we introduce representative ROS-generating and ROS-scavenging nanozymes and discuss how artificial nanozymes respond to the conditions of the TME. Based on the mutual interaction between nanozymes and TME, recent therapeutic pathways to provoke anti-cancer immune responses using nanozymes are discussed.
© 2022. The Korean Tissue Engineering and Regenerative Medicine Society.

Entities:  

Keywords:  Cancer immunotherapy; Immunogenic cell death; Nanozymes; Reactive oxygen species; Tumor microenvironment

Mesh:

Substances:

Year:  2022        PMID: 35099759      PMCID: PMC8971237          DOI: 10.1007/s13770-022-00430-y

Source DB:  PubMed          Journal:  Tissue Eng Regen Med        ISSN: 1738-2696            Impact factor:   4.169


  61 in total

1.  Injectable dual-scale mesoporous silica cancer vaccine enabling efficient delivery of antigen/adjuvant-loaded nanoparticles to dendritic cells recruited in local macroporous scaffold.

Authors:  Thanh Loc Nguyen; Bong Geun Cha; Youngjin Choi; Jihye Im; Jaeyun Kim
Journal:  Biomaterials       Date:  2020-02-10       Impact factor: 12.479

Review 2.  Combining immunotherapy and targeted therapies in cancer treatment.

Authors:  Matthew Vanneman; Glenn Dranoff
Journal:  Nat Rev Cancer       Date:  2012-03-22       Impact factor: 60.716

Review 3.  Immune checkpoint blockade: a common denominator approach to cancer therapy.

Authors:  Suzanne L Topalian; Charles G Drake; Drew M Pardoll
Journal:  Cancer Cell       Date:  2015-04-06       Impact factor: 31.743

Review 4.  Towards personalized, tumour-specific, therapeutic vaccines for cancer.

Authors:  Zhuting Hu; Patrick A Ott; Catherine J Wu
Journal:  Nat Rev Immunol       Date:  2017-12-11       Impact factor: 53.106

Review 5.  Personalized vaccines for cancer immunotherapy.

Authors:  Ugur Sahin; Özlem Türeci
Journal:  Science       Date:  2018-03-23       Impact factor: 47.728

Review 6.  Therapeutic vaccines for cancer: an overview of clinical trials.

Authors:  Ignacio Melero; Gustav Gaudernack; Winald Gerritsen; Christoph Huber; Giorgio Parmiani; Suzy Scholl; Nicholas Thatcher; John Wagstaff; Christoph Zielinski; Ian Faulkner; Håkan Mellstedt
Journal:  Nat Rev Clin Oncol       Date:  2014-07-08       Impact factor: 66.675

7.  Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens.

Authors:  Matthew M Gubin; Xiuli Zhang; Heiko Schuster; Etienne Caron; Jeffrey P Ward; Takuro Noguchi; Yulia Ivanova; Jasreet Hundal; Cora D Arthur; Willem-Jan Krebber; Gwenn E Mulder; Mireille Toebes; Matthew D Vesely; Samuel S K Lam; Alan J Korman; James P Allison; Gordon J Freeman; Arlene H Sharpe; Erika L Pearce; Ton N Schumacher; Ruedi Aebersold; Hans-Georg Rammensee; Cornelis J M Melief; Elaine R Mardis; William E Gillanders; Maxim N Artyomov; Robert D Schreiber
Journal:  Nature       Date:  2014-11-27       Impact factor: 49.962

Review 8.  Hypoxia-Driven Immune Escape in the Tumor Microenvironment.

Authors:  Alyssa Vito; Nader El-Sayes; Karen Mossman
Journal:  Cells       Date:  2020-04-16       Impact factor: 6.600

Review 9.  Therapeutic cancer vaccines: past, present, and future.

Authors:  Chunqing Guo; Masoud H Manjili; John R Subjeck; Devanand Sarkar; Paul B Fisher; Xiang-Yang Wang
Journal:  Adv Cancer Res       Date:  2013       Impact factor: 6.242

View more
  3 in total

1.  Nano-sized Materials for Tissue Regeneration and Immune/Cancer Therapy.

Authors:  Suk Ho Bhang; Inho Jo
Journal:  Tissue Eng Regen Med       Date:  2022-04       Impact factor: 4.169

2.  Enhancement of anti-tumor activity in melanoma using arginine deiminase fused with 30Kc19α protein.

Authors:  Haein Lee; Geunhwa Park; Seulha Kim; Boram Son; Jinmyoung Joo; Hee Ho Park; Tai Hyun Park
Journal:  Appl Microbiol Biotechnol       Date:  2022-10-13       Impact factor: 5.560

Review 3.  Oxidative Stress in Cancer Immunotherapy: Molecular Mechanisms and Potential Applications.

Authors:  Ruolan Liu; Liyuan Peng; Li Zhou; Zhao Huang; Chengwei Zhou; Canhua Huang
Journal:  Antioxidants (Basel)       Date:  2022-04-27
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.